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ORIGINAL ARTICLE
Cryptic splicing events in the iron transporter ABCB7 and
other key target genes in SF3B1-mutant myelodysplastic
syndromes
H Dolatshad1,2,8, A Pellagatti1,2,8, FG Liberante3, M Llorian4, E Repapi5, V Steeples1,2, S Roy1,2, L Scifo1,2, RN Armstrong1,2, J Shaw1,2,
BH Yip1,2, S Killick6, R Kušec7, S Taylor5, KI Mills3, KI Savage3, CWJ Smith4 and J Boultwood1,2
The splicing factor SF3B1 is the most frequently mutated gene in myelodysplastic syndromes (MDS), and is strongly associated with
the presence of ring sideroblasts (RS). We have performed a systematic analysis of cryptic splicing abnormalities from RNA
sequencing data on hematopoietic stem cells (HSCs) of SF3B1-mutant MDS cases with RS. Aberrant splicing events in many
downstream target genes were identiﬁed and cryptic 3′ splice site usage was a frequent event in SF3B1-mutant MDS. The iron
transporter ABCB7 is a well-recognized candidate gene showing marked downregulation in MDS with RS. Our analysis unveiled
aberrant ABCB7 splicing, due to usage of an alternative 3′ splice site in MDS patient samples, giving rise to a premature termination
codon in the ABCB7 mRNA. Treatment of cultured SF3B1-mutant MDS erythroblasts and a CRISPR/Cas9-generated SF3B1-mutant cell
line with the nonsense-mediated decay (NMD) inhibitor cycloheximide showed that the aberrantly spliced ABCB7 transcript is
targeted by NMD. We describe cryptic splicing events in the HSCs of SF3B1-mutant MDS, and our data support a model in which
NMD-induced downregulation of the iron exporter ABCB7mRNA transcript resulting from aberrant splicing caused by mutant SF3B1
underlies the increased mitochondrial iron accumulation found in MDS patients with RS.
Leukemia advance online publication, 17 June 2016; doi:10.1038/leu.2016.149
INTRODUCTION
The myelodysplastic syndromes (MDS) are a heterogeneous
group of clonal hematopoietic stem cell (HSC) malignancies
characterized by ineffective hematopoiesis leading to peripheral
blood cytopenias, and show increasing bone marrow blasts.1
The MDS show frequent progression (approximately 40% of
patients) to acute myeloid leukemia. Several genes involved in
pre-messenger RNA splicing, including SF3B1, U2AF1, SRSF2 and
ZRSR2,2–4 have been shown to be mutated in over 50% of MDS
patients, revealing a new leukemogenic pathway involving
spliceosomal dysfunction.
The splicing factor SF3B1 is the most frequently mutated gene
in patients with MDS (20–28% of all cases).5,6 Mutations of SF3B1
occur in a high proportion (480%) of MDS patients in whom
the presence of ring sideroblasts (RS) is a characteristic disease
feature, namely the refractory anemia with RS (RARS) and
refractory cytopenia with multilineage dysplasia and RS
(RCMD-RS) subtypes.5,7 In the recent 2016 revision of the World
Health Organization (WHO) classiﬁcation for MDS, if a patient
harbors an SF3B1 mutation, a diagnosis of MDS with RS (MDS-RS)
may be made if 5–14% RS are present in the bone marrow.8
SF3B1 mutations are closely associated with the presence of RS,
suggesting a causal relationship and making SF3B1 the ﬁrst gene
showing a strong association with a particular morphological
feature in MDS.5 RS are erythroblasts with excessive mitochondrial
iron accumulation,9 and RARS patients with SF3B1 mutation have
altered iron distribution characterized by coarse iron deposits in
comparison with RARS patients without SF3B1 mutation.10 SF3B1
mutations occur more frequently in low-risk MDS cases and are
independent predictors of favorable survival in MDS.5 The clinical
consequences of mutations in SF3B1 are well documented in MDS,
however the functional consequences of SF3B1 mutations in
human hematopoietic cells are not fully understood.
A well-recognized candidate gene for MDS with the RS
phenotype is the iron transporter ABCB7. Our group ﬁrst reported
marked downregulation of ABCB7 in MDS patients with RARS
subtype.11 Hereditary X-linked sideroblastic anemia with ataxia is
caused by partial loss-of-function mutations of ABCB7, which
inhibit heme biosynthesis.12 Moreover, knockdown of ABCB7 in
HeLa cells resulted in an iron-deﬁcient phenotype with mitochon-
drial iron accumulation.13 Conditional gene targeting in mice has
shown that ABCB7 is essential for hematopoiesis.12
SF3B1 is a core component of the U2-small nuclear ribonucleo-
protein complex and is involved in stabilizing the interaction of
the U2-small nuclear ribonucleoprotein with the branch point
(BP),14 upstream of the 3′ splice site. SF3B1 also interacts with
other spliceosomal proteins such as U2AF2, which binds the
polypyrimidine tract (PPT) downstream of the BP.15,16 Base-pairing
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of U2 snRNA with the pre-messenger RNA bulges out the BP
adenosine, specifying it as the site to initiate the nucleophilic
attack in the ﬁrst step of splicing. The binding of the SF3B complex
proteins around the BP prevents the premature activity at the site
before the fully active spliceosome is assembled.17 The role of
SF3B1 and the U2-small nuclear ribonucleoprotein in recognizing
and binding the BP suggest that SF3B1 mutations may alter BP
and/or 3′ splice site selection.
The splicing factor genes found to be mutated in MDS code for
proteins that have a role in the recognition of 3′ splice sites during
processing of pre-messenger RNAs.3 Altered RNA splicing has
been suggested as the mechanism underlying the observed
phenotypic changes concomitant to splicing factor gene
mutations, including SF3B1, and the identiﬁcation of aberrantly
spliced target genes in the hematopoietic cells of SF3B1-mutant
MDS cases is important.
A number of studies to date have used RNA sequencing
(RNA-Seq) on unfractionated bone marrow mononuclear cells
from a small number of SF3B1-mutant MDS patients.10,18,19 MDS is
a disorder of the HSC and we thus studied the transcriptome of
CD34+ cells from MDS patients with SF3B1 mutations using
RNA-Seq. We have recently identiﬁed many genes signiﬁcantly
differentially expressed at the transcript and/or exon level in bone
marrow CD34+ cells of SF3B1-mutant MDS compared with
wild-type and healthy control cases.20
Recently, SF3B1 mutations have been identiﬁed in various
tumor types, suggesting that somatic mutations in spliceosome
genes have an important role in tumorigenesis.21–24 SF3B1
mutations have been shown to occur in chronic lymphocytic
leukemia, uveal melanoma, breast cancer and pancreatic
cancer.24,25 SF3B1 mutations have clear mutational hotspots
and are considered to be gain-of-function/neomorphic muta-
tions.2,3,26,27 The codons most commonly affected by SF3B1
mutations in other cancers that harbor this mutation, including
chronic lymphocytic leukemia, uveal melanoma, breast cancer and
pancreatic cancer, are the same as the ones affected in MDS (K700,
R625 and K666). Recent studies of chronic lymphocytic leukemia,
breast cancer and uveal melanoma using RNA-Seq have shown
that SF3B1 mutations are associated with differential exon usage
and induce cryptic alternative 3′ splice site selection in these
cancers.28 However, a systematic analysis of cryptic splicing
abnormalities has not been performed in MDS HSCs.
In this study, we have performed an analysis of RNA-Seq data
on HSCs of SF3B1-mutant MDS cases to identify aberrant/cryptic
splicing events. The identiﬁcation of the splicing aberrations
induced by SF3B1 mutation in the HSCs of MDS patients will shed
light on the downstream effects that lead to the MDS phenotype
and may allow for the identiﬁcation of new therapeutic targets in
this disease.
MATERIALS AND METHODS
Samples and RNA-Seq
RNA-Seq data were obtained from CD34+ cells isolated from bone
marrow samples of eight MDS patients (four RARS and four RCMD-RS)
with SF3B1 mutation (four K700E, one E622D, one R625L, one H662Q and
one K666R; 45–52% SF3B1-mutant allele expression range), four MDS
cases (all refractory cytopenia with multilineage dysplasia) without
mutations in the splicing factor genes SF3B1, SRSF2, U2AF1 and ZRSR2,
and ﬁve healthy individuals.20 CD34+ cells were isolated from bone
marrow samples of the 12 MDS patients and ﬁve healthy controls using
magnetic-activated cell sorting columns (Miltenyi Biotec, Bergisch
Gladbach, Germany), according to the manufacturer’s recommendations.
DNase-treated (Invitrogen, Carlsbad, CA, USA) total RNA was puriﬁed
using XP beads (Beckman Coulter, High Wycombe, UK), and library
preparation was performed using the NEBNext Ultra directional RNA
Library prep kit (NEB, Hitchin, UK) following the manufacturer’s recom-
mendations. Custom indexes were used and samples were puriﬁed using
XP beads (Beckman Coulter) instead of size selection. Sequencing was
performed on an Illumina HiSeq2000 instrument (Illumina, San Diego, CA,
USA).
RNA-Seq data analysis
Following QC analysis with the fastQC package (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc), reads were aligned using STAR29 against
the human genome assembly (NCBI build37 (hg19) UCSC transcripts).
Non-uniquely mapped reads and reads that were identiﬁed as PCR
duplicates using Samtools30 were discarded. The aligned reads were
reconstructed into transcripts using Cufﬂinks31 and were then merged into
a single assembly, along with known isoforms from the NCBI build37
(hg19) UCSC transcripts. This reference-guided assembly was then used as
the transcripts annotation by rMATS.
Alternative 3′ and 5′ splice sites, skipped exons, mutually exclusive
exons and retained introns were quantiﬁed using rMATS32 with the
assembly produced from Cufﬂinks. The default parameters were used for
the comparison of the samples. The results were ﬁltered using a false
discovery rateo0.05 and inclusion level difference values 40.3 or
o − 0.3. The alternative spliced events were then plotted using the
sashimi plots of the MISO software.33 The results were visualized and
ﬁltered using the data visualization tool Zegami (http://zegami.com/).
Gene ontology analysis
See Supplementary Methods.
Analysis of 3′ splice site properties
See Supplementary Methods.
End point RT-PCR validation of aberrant splicing isoforms
Six genes (including ABCB7) with cryptic 3′ splice sites were selected from
the rMATS data analysis for end point reverse transcriptase-PCR (RT-PCR)
validation. See Supplementary Methods for details.
Erythroblast cell culture and cycloheximide treatment
Bone marrow CD34+ cells from healthy individuals were purchased from
Lonza (Basel, Switzerland). Bone marrow samples were obtained and
CD34+ cells were isolated from two MDS patients with SF3B1 K700E
mutation. CD34+ cells from MDS patients and from healthy controls were
cultured as previously described.34,35 On day 11 and day 14, an aliquot of
cells were treated with 100 μg/ml cycloheximide for 4 h and subsequently
collected for RNA extraction. Total RNA was reverse-transcribed using High
capacity cDNA reverse transcription kit (Applied Biosystems, Foster City,
CA, USA). The expression of aberrantly spliced ABCB7 was determined by
RT-PCR as described in the Supplementary Methods.
Generation of SF3B1-mutant K562 cells by CRISPR/Cas9 and
cycloheximide treatment
See Supplementary Methods.
Pancreatic cell line Panc 05.04 culture and cycloheximide
treatment
See Supplementary Methods.
RESULTS
Cryptic splicing events in HSCs of SF3B1-mutant MDS
We have analyzed RNA-Seq data obtained from the CD34+ cells
from eight MDS cases harboring SF3B1 mutations (SF3B1-mutant,
all with415% RS), four MDS patients without splicing factor gene
mutations (wild type) and ﬁve healthy individuals (control)20 using
rMATS, a bioinformatics pipeline designed to detect alternative
(including cryptic) splicing events involving two isoforms from an
alternatively spliced region.32 These events are categorized as
alternative 3′ splice site (A3SS) usage, alternative 5′ splice site
(A5SS) usage, exon skipping, mutually exclusive exons or retained
introns.
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When comparing SF3B1-mutant to wild type, we identiﬁed 126
signiﬁcant splicing events (92 genes), of which 42 were A3SS, 6
A5SS, 8 mutually exclusive exons, 13 skipped exons and 57
retained introns (Tables 1 and 2, Supplementary Table S1). When
comparing SF3B1-mutant with controls, 213 signiﬁcant splicing
events (164 genes) were identiﬁed, of which 62 were A3SS, 10
A5SS, 12 mutually exclusive exon, 12 skipped exons and 117
retained intron (Tables 1 and 3, Supplementary Table S2).
Top-ranking signiﬁcant genes showing at least one cryptic splicing
event in both of these comparisons include TMEM14C, ENOSF1,
SEPT6, DYNLL1, HINT2 and ABCC5.
We performed gene ontology analysis on the lists of signiﬁcant
genes showing aberrant splicing events identiﬁed by the rMATS
pipeline using GOseq. The signiﬁcant main ontology themes for
the comparison of SF3B1-mutant with wild type and controls
include ‘RNA processing’ and ‘RNA splicing’ (Supplementary Tables
S3 and S4).
Properties of misregulated alternative 3′ splice sites
Compared with all alternative splicing events (regulated and
unregulated) detected in the data by rMATS, we found a
signiﬁcant overrepresentation of regulated A3SS (Po1 × E-08,
χ2-test with Yates's continuity correction), but no signiﬁcant
overrepresentation of alternative 5′ splice sites, in the comparison
of SF3B1-mutant with both wild type and controls (Table 1).
Indeed, 15/20 (75%) most signiﬁcant aberrant splicing events in
the comparison of SF3B1-mutant with wild type (Table 2) and
13/20 (65%) most signiﬁcant aberrant splicing events in the
comparison of SF3B1-mutant with controls (Table 3) were A3SS.
These data are in accord with the known function of SF3B1 in the
recognition of BPs and 3′ splice sites. In addition to A3SS, retained
introns were also signiﬁcantly overrepresented, while cassette and
mutually exclusive exons were underrepresented.
The majority of the regulated A3SS events involved use of an
A3SS upstream of the canonical 3′ splice site (Table 1). Analysis of
the sequences of upstream and downstream cryptic 3′ splice sites,
along with their associated canonical 3′ splice sites revealed
distinct sequence features. Both sets of canonical 3′ splice sites
had extensive 18–20 nt PPTs with enrichment of uridines at most
positions (Figure 1a, Supplementary Figure S1A). In contrast, the
upstream cryptic sites had a shorter PPT of ~ 8 nt with a stretch of
4–5A residues 13–17 nt upstream. Downstream cryptic sites in the
Table 1. Number of signiﬁcant cryptic splicing events in the comparison of SF3B1-mutant MDS cases with wild-type MDS cases and with healthy
controls, and breakdown by event type
Mutant vs wild
type
P-value Direction of change wt-mut Mutant vs
Control
P-value Direction of change HC - mut
No. of signiﬁcant events
(genes)
126 (92) +/− 213 (164) +/−
A3SS 42 o1e-8 Overrepresented 21/21 62 o1e-8 Overrepresented 25/37
A5SS 6 0.236 Not signiﬁcant 6/0 10 0.38 Not signiﬁcant 9/1
MXE 8 0.00002 Underrepresented 2/6 12 0.0047 Underrepresented 2/10
RI 57 o1e-8 Overrepresented 55/2 117 o1e-8 Overrepresented 115/2
SE 13 o1e-8 Underrepresented 5/8 12 o1e-8 Underrepresented 3/9
Abbreviations: A3SS, alternative 3′ splice site usage; A5SS, alternative 5′ splice site usage; MXE, mutually exclusive exons; RI, retained introns; SE, exon skipping.
The P-value was obtained by Chi-squared test with Yates' correction comparing the proportion of signiﬁcant events of each type to the proportion of total
events of that type.
Table 2. List of the 20 most signiﬁcant cryptic splicing events in the comparison of SF3B1-mutant MDS cases with wild-type MDS cases
GeneID geneSymbol event_type event_class chr strand start_loc end_loc IncLevelDifference P-value FDR
XLOC_028687 ORAI2 A3SS Both chr7 + 102073977 102076780 − 0.732 0 0
XLOC_005007 CCDC88B A3SS Both chr11 + 64119602 64120359 − 0.647 0 0
XLOC_025420 TMEM14C A3SS Both chr6 + 10723148 10724866 − 0.623 0 0
XLOC_024609 ZDHHC11 SE Both chr5 − 865529 870690 − 0.558 0 0
XLOC_008832 DLST A3SS Both chr14 + 75355978 75356655 − 0.552 0 0
XLOC_014206 ENOSF1 A3SS Both chr18 − 683246 686008 − 0.538 0 0
XLOC_033494 SEPT6 A3SS Both chrX − 118759298 118763471 − 0.519 0 0
XLOC_026718 MICAL1 A3SS Both chr6 − 109766974 109767615 − 0.517 0 0
XLOC_006947 DYNLL1 A3SS Both chr12 + 120933859 120934356 − 0.485 0 0
XLOC_012879 MYO15B A3SS Both chr17 + 73587253 73587793 − 0.471 0 0
XLOC_031822 HINT2 A3SS Both chr9 − 35812957 35813335 − 0.408 0 0
XLOC_012879 MYO15B SE Both chr17 + 73597519 73598675 − 0.394 0 0
XLOC_002049 SERBP1 A3SS Both chr1 − 67890571 67890906 − 0.336 0 0
XLOC_012590 COASY RI Both chr17 + 40713975 40715340 0.44 0 0
XLOC_028659 PILRB A3SS Both chr7 + 99954373 99955989 0.488 0 0
XLOC_024347 ANKHD1-EIF4EBP3 A3SS Both chr5 + 139815689 139818202 0.598 2.55E-15 1.77E-12
XLOC_021918 UBA7 RI Both chr3 − 49848417 49848888 0.444 6.66E-16 2.15E-12
XLOC_012879 MYO15B RI Both chr17 + 73583687 73587793 0.307 2.51E-14 5.41E-11
XLOC_026672 MAP3K7 A3SS Both chr6 − 91269795 91271386 -0.649 2.37E-13 1.44E-10
XLOC_028659 PILRB A3SS Both chr7 + 99943488 99947510 -0.441 2.84E-13 1.65E-10
Abbreviations: A3SS, alternative 3′ splice site usage; A5SS, alternative 5′ splice site usage; FDR, false discovery rate; RI, retained introns; SE, exon skipping. The
'− ' sign in the IncLevelDifference corresponds to the longer isoform (exon inclusion, retained intron, upstream A3SS, downstream A5SS) being produced in
SF3B1-mutant cells. Conversely, the '+' sign in the IncLevelDifference corresponds to upregulation of the longer isoform in wild-type MDS cases.
Cryptic splicing events in SF3B1-mutant MDS
H Dolatshad et al
3
Leukemia (2016), 1 – 10
Table 3. List of the 20 most signiﬁcant cryptic splicing events in the comparison of SF3B1-mutant MDS cases with healthy controls
GeneID geneSymbol event_type event_class chr strand start_loc end_loc IncLevelDifference P-value FDR
XLOC_028687 ORAI2 A3SS Both chr7 + 102073977 102076780 -0.726 0 0
XLOC_025420 TMEM14C A3SS Both chr6 + 10723148 10724866 -0.652 0 0
XLOC_026672 MAP3K7 A3SS Both chr6 − 91269795 91271386 -0.641 0 0
XLOC_024609 ZDHHC11 SE Both chr5 − 865529 870690 -0.586 0 0
XLOC_008832 DLST A3SS Both chr14 + 75355978 75356655 -0.546 0 0
XLOC_014206 ENOSF1 A3SS Both chr18 − 683246 686008 -0.523 0 0
XLOC_033494 SEPT6 A3SS Both chrX − 118759298 118763471 -0.52 0 0
XLOC_026718 MICAL1 A3SS Both chr6 − 109766974 109767615 -0.509 0 0
XLOC_010867 CHTF18 A3SS Both chr16 + 843144 844201 -0.498 0 0
XLOC_006947 DYNLL1 A3SS Both chr12 + 120933859 120934356 -0.482 0 0
XLOC_012879 MYO15B A3SS Both chr17 + 73587253 73587793 -0.457 0 0
XLOC_012879 MYO15B SE Both chr17 + 73597519 73598675 -0.379 0 0
XLOC_015516 SAFB2 MXE Both chr19 − 5592757 5598895 -0.365 0 0
XLOC_031822 HINT2 A3SS Both chr9 − 35812957 35813335 -0.348 0 0
XLOC_002049 SERBP1 A3SS Both chr1 − 67890571 67890906 -0.336 0 0
XLOC_016489 TMEM214 MXE Both chr2 + 27260429 27261683 -0.317 0 0
XLOC_025420 TMEM14C MXE Both chr6 + 10723148 10726241 -0.305 0 0
XLOC_025700 ADCY10P1 A3SS Both chr6 + 41040701 41046903 -0.3 0 0
XLOC_012879 MYO15B RI Both chr17 + 73583687 73587793 0.356 0 0
XLOC_020345 GTSE1 RI Both chr22 + 46722333 46725464 0.363 0 0
Abbreviations: A3SS, alternative 3′ splice site usage; A5SS, alternative 5′ splice site usage; FDR, false discovery rate; MXE, mutually exclusive exons; RI, retained
introns; SE, exon skipping. The '− ' sign in the IncLevelDifference corresponds to the longer isoform (exon inclusion, retained intron, upstream A3SS,
downstream A5SS) being produced in SF3B1-mutant cells. Conversely, the '+' sign in the IncLevelDifference corresponds to upregulation of the longer isoform
in the healthy controls.
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Figure 1. Properties of A3SS misregulated in SF3B1-mutant compared with wild-type SF3B1 MDS HSCs. (a) Sequence logos for upstream and
downstream cryptic 3′ splice sites along with their associated canonical sites. (b) Density plot showing distance (log2) between pairs of 3′
splice sites. Blue line: upstream cryptic. Red line: downstream cryptic. Green line: A3SS unaffected by SF3B1 mutation. (c) 3′ splice site
strengths (maximum entropy) for upstream and downstream control (unregulated) A3SS, upstream cryptic sites and their associated
canonical sites, and downstream cryptic sites and their associated canonical sites. (d) BP scores. (e) Distance of highest scoring predicted BP
from associated 3′ splice site. (*Po0.05, **Po0.01).
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comparison of SF3B1-mutant with wild type also had more purine
interruptions (Figure 1a), but this was not evident in the
comparison of SF3B1-mutant with control (Supplementary
Figure S1A). Analysis of the distance separating pairs of A3SS
revealed a very distinct pattern for upstream cryptic 3′ splice sites,
with a strong peak at 15nt (Figure 1b, Supplementary Figure S1B,
blue trace; 15nt = 3.9 on log2 scale). In contrast, downstream
cryptic 3′ splice sites and A3SS unregulated by the SF3B1 mutation
showed a much broader distribution of spacing with most pairs of
A3SS being much more widely spaced (red and green traces in
Figure 1b and Supplementary Figure S1B). One interesting
exception was a peak at 3 nt (1.6 on log2 scale) for the
unregulated A3SS, which corresponds to the so-called NAGNAG
class of A3SS,36 selection of which occurs at step 2 of splicing37
consistent with a lack of effect of SF3B1 mutation. Comparison of
3′ splice site strength showed that both upstream and
Figure 2. Validation and semi-quantiﬁcation of cryptic 3′ splice site usage in ﬁve selected genes from the rMATS analysis in SF3B1-mutant MDS
HSC samples. (a) PCR products of the ﬁve genes (TMEM14C, ENOSF1, DYNLL1, SEPT6 and HINT2) were ampliﬁed from SF3B1-mutant MDS
samples (Mut), wild-type MDS samples (WT) and healthy control samples (HC) run on an Agilent 2100 Bioanalyzer instrument using the DNA
1000 kit. The aberrant transcripts (indicated by the higher band) were observed in the SF3B1-mutant MDS samples. (b) Semi-quantiﬁcation of
the PCR bands showed high cryptic to canonical isoform ratio in the SF3B1-mutant MDS samples.
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downstream cryptic 3′ splice sites were weaker than their
associated canonical sites in the comparison of SF3B1-mutant
with wild type (Figure 1c), but in the comparison of SF3B1-mutant
with controls, only the upstream cryptic sites were weaker
(Supplementary Figure S1C). This is consistent with the adenosine
interruptions of the PPT in the upstream cryptic sites (Figure 1a,
Supplementary Figure S1A). We used SVM-BP ﬁnder38 to predict
the location and strength of the top-scoring predicted BPs
associated with each A3SS. Although the predicted BP scores
did not differ signiﬁcantly between sets of regulated cryptic 3′
splice site and their associated canonical sites (Figure 1d,
Supplementary Figure S1D), top-scoring BPs for upstream cryptic
sites were closer (median 18nt, BP-AG distance) than those for
their associated canonical sites (median 27nt) or unregulated A3SS
(median 26nt) (Figure 1e, Supplementary Figure S1E). Taken
together, our data show that MDS-associated SF3B1 mutations
result in widespread use of cryptic 3′ splice sites a short distance
upstream of canonical sites and could be consistent either with
use of a common BP in association with upstream cryptic and
canonical splice site pairs28 or, more likely, with shifted use of both
BP and consequently 3′ splice site in the SF3B1-mutant,39,40 as
shown in recent reports in other cancers.
Validation of cryptic 3′ splice site events
Several of the misregulated A3SS events identiﬁed by the rMATS
pipeline were validated using RT-PCR in patient and healthy
control samples. We chose TMEM14C, SEPT6, HINT2, DYNLL1 and
ENOSF1 for validation. These genes all showed upstream cryptic 3′
splice sites in the rMATS analysis with the cryptic AG site located
between 11 and 17 nucleotides upstream of the canonical site
(Supplementary Figure S2). Aberrant splicing of TMEM14C and
DYNLL1 introduces an addition of 14 base pairs in the 5′UTR
region of these genes. The cryptic splice site event in ENOSF1
leads to the addition of 15 base pairs (encoding ﬁve amino acids)
to the coding sequence. Aberrant splicing of SEPT6 and HINT2
introduces an addition of 17 and 11 base pairs, respectively,
leading to a frameshift in SEPT6 and to the rise of a premature
termination codon in the ﬁrst 3 base pairs of exon 5 in HINT2. The
RT-PCR results conﬁrmed the cryptic splicing events identiﬁed by
RNA-Seq in these ﬁve genes in MDS patient samples with SF3B1
mutation (Figures 2a and b).
Cryptic splicing of ABCB7 in HSCs of SF3B1-mutant MDS
We previously reported marked downregulation of the iron
transporter ABCB7 in MDS patients with RS.11 In this study, we
identiﬁed a signiﬁcant A3SS event (false discovery rate = 0.006,
inclusion level difference =− 0.184) in the ABCB7 gene in the
comparison of SF3B1-mutant with controls. Aberrant splicing
introduces an addition of 21 base pairs from the intronic region
between exons 8 and 9 causing an addition of seven amino acids
to the protein sequence with the last 3 base pairs proximal to the
canonical exon 9 giving rise to a premature termination codon
(Figures 3a and b). This result was conﬁrmed by RT-PCR in patient
and healthy control HSC samples: the aberrant ABCB7 transcript
was observed in all SF3B1-mutant MDS samples analyzed (n= 7),
but not in any of the samples from wild-type patients (n= 4) or
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from healthy controls (n= 5) (Figure 4a). Sanger sequencing of gel
extract bands conﬁrmed the presence of the addition of 21 base
pairs in the aberrant ABCB7 transcript (Figure 3b). These data
demonstrate that aberrant splicing of ABCB7 observed is speciﬁc
to MDS cases carrying mutation of SF3B1.
NMD targets the aberrantly spliced ABCB7 transcript in SF3B1-
mutant MDS erythroblasts, isogenic K562-SF3B1K700E and a SF3B1-
mutant pancreatic cell line
The presence of premature termination codons can lead to
degradation of mRNA transcripts by nonsense-mediated RNA
decay (NMD).41 We thus investigated whether the aberrantly
spliced ABCB7 transcript containing a premature termination
codon that we identiﬁed in SF3B1-mutant MDS is affected by
NMD. CD34+ cells from two SF3B1-mutant MDS RARS patients and
from two healthy controls were cultured using a method
developed to study the generation of erythroblasts.34,35 Cells
were collected at day 11 and day 14 of erythroid culture and
treated with cycloheximide (an inhibitor of protein biosynthesis
known to impair NMD42), and subjected to RT-PCR for ABCB7. The
RT-PCR results showed an increase in the product corresponding
to the aberrant ABCB7 transcript in the SF3B1-mutant patient
samples treated with cycloheximide compared with untreated
samples (Figure 4b), indicating that NMD targets the aberrantly
spliced ABCB7 transcript and underlies the downregulation of
ABCB7 observed in SF3B1-mutant MDS patients.
In addition, we performed RT-PCR for ABCB7 in K562-SF3B1K700E
and SF3B1WT isogenic cells obtained using CRISPR/Cas9 gene
editing and the pancreatic cell line Panc 05.04, which has a
heterozygous SF3B1 K700E mutation, and we observed the same
ABCB7 cryptic 3′ splice site event (Figures 4c and d), which
introduces a stop codon as identiﬁed in the CD34+ cells and
cultured erythroblasts of SF3B1-mutant MDS patients. Treatment
of K562-SF3B1K700E and Panc 05.04 cells with cycloheximide
resulted in an increase of the aberrantly spliced form of the ABCB7
transcript (Figures 4c and d).
DISCUSSION
The splicing factor SF3B1 is the most frequently mutated gene
found in MDS, and is strongly associated with the RS phenotype.5,6
It is still unknown how SF3B1 mutations lead to the formation of
RS in MDS. Given the critical functions of SF3B1 on 3′ splice site
recognition, the probable consequence of this spliceosome
mutation is aberrant splicing of various downstream target genes
in MDS. The MDS arise in the HSC population in the bone marrow
and SF3B1 is a founder mutation.43,44 It is important to study the
impact of SF3B1 mutation on the transcriptome in the cell of
origin. We sought to identify the aberrant/cryptic mRNA splicing
events associated with the SF3B1 mutation in the HSCs of MDS
patients. We performed an analysis of RNA-Seq data that we
generated from CD34+ cells isolated from bone marrow samples
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of SF3B1-mutant MDS patients with RS, MDS patients with no
splicing factor gene mutation and from healthy individuals.20
The recent identiﬁcation of A3SS usage in other malignancies
with SF3B1 mutation22,28 highlights the importance of interrogat-
ing RNA-seq data using a method that allows the identiﬁcation of
not only annotated alternative splicing events, but also of de novo
cryptic splicing events. In this study, we used de novo
transcriptome reconstruction and the rMATS pipeline to identify
unannotated alternative splicing events, including A3SS and
retained introns. We have found that SF3B1 mutations are
associated with various aberrant splicing events in the HSCs of
MDS patients. Interestingly, we identiﬁed signiﬁcant cryptic 3′
splice site usage affecting many genes when comparing the
transcriptome of SF3B1-mutant MDS cases with that of MDS wild-
type and control cases, in accord with the known role of SF3B1 in
the recognition of 3′ splice sites. A3SS events were signiﬁcantly
overrepresented in both comparisons, but no signiﬁcant over-
representation of alternative 5′ splice sites was observed. Indeed,
the majority (65–75%) of the most signiﬁcant aberrant splicing
events in the comparison of SF3B1-mutant with both wild type
and controls were A3SS. Furthermore, the number of genes with
A3SS was sixfold to sevenfold higher than the number of genes
with alternative 5′ splice sites. These data show that aberrant 3′
splice site selection is a frequent and important event associated
with SF3B1 mutations in the HSCs of MDS patients.
The most distinct group of misregulated events in SF3B1-
mutant MDS involved the use of cryptic 3′ splice sites located 15–
20 nt upstream of the canonical 3′ splice site, consistent with
recent reports in other cancers.28,39,40 This is an unusual location
as the typical 3′ splice site arrangement comprises a BP typically
18–40 nt upstream of the 3′ splice site, with an optimal separation
of 19–23 nt45 and a minimal separation of ~ 12 nt.37 The 15 nt
separation of A3SS could therefore be consistent with a single BP-
PPT unit from which either of two 3′ splice sites can be used,28
similar to Drosophila SXL exon 3.46 Alternatively, SF3B1 mutations
could lead to a shift in BP selection a short distance upstream
leading to altered 3′ splice site selection.39,40 For the six events
that we investigated, the predicted and mapped BP locations
support the second scenario in which altered BP selection drives
the change in 3′ splice site selection in MDS (Supplementary
Figure S2). This would be consistent with the recruitment of U2-
small nuclear ribonucleoprotein to positions 5′ of the BP in
response to SF3B1 targeting drugs.47 Emerging data suggest that
myeloid malignancies with splicing factor gene mutations are
preferentially susceptible to additional splicing perturbations
induced by splicing factor inhibitors48 and this may also represent
a therapeutic approach in SF3B1-mutant MDS.
In our study, we found at least one cryptic splicing event in
TMEM14C, ENOSF1, DYNLL1, SEPT6 and HINT2 (validated by RT-PCR)
when comparing SF3B1-mutant to wild type and to controls.
Importantly, cryptic splicing events affecting TMEM14C, ENOSF1,
DYNLL1 and HINT2 have been associated with SF3B1 mutation in
other cancers such as chronic lymphocytic leukemia, uveal
melanoma and breast cancer.21–23 Emerging evidence thus
suggests that there are several common downstream target
genes in SF3B1-mutant malignancies, which may have implica-
tions for the design of new therapies for this group of cancers.
It is most probable that several target genes showing cryptic
splicing contribute to the phenotype observed in MDS patients
with the SF3B1 mutation. We note for example that TMEM14C has
an important role in the terminal steps of the heme synthesis
pathway.49
MDS patients with RARS suffer from a refractory anemia
and show erythroid hyperplasia and ineffective erythropoiesis
as a result of increased apoptosis in the bone marrow.50 RS are
characterized by excessive iron accumulation in the mitochondria
of erythroid progenitors.9 The close association between SF3B1
mutations and RS is consistent with a causal relationship, and
makes this the ﬁrst gene to be strongly associated with a speciﬁc
feature of MDS.5 How SF3B1 mutations affect formation of RS is
still unknown.
Cryptic splicing of genes involved in iron homeostasis and/or
hemoglobin synthesis could have a role in the ineffective
erythropoiesis observed in MDS patients with SF3B1 mutation and
RS.51 We reported some years ago a strong relationship between
an increasing percentage of bone marrow RS in MDS patients and
decreasing expression levels of the iron transporter ABCB7.11 The
ABCB7 gene is the functional ortholog of the yeast Atm1p gene,52
which has been shown to be required for mitochondrial iron
homeostasis53 and is involved in the transport of a component
required for the maturation of iron-sulfur cluster proteins from the
mitochondria to the cytosol.12 Functional studies showing that
forced expression of ABCB7 can restore erythroid growth and
survival of RARS progenitors while decreasing the expression of
aberrant mitochondrial ferritin (a marker for aberrant iron
accumulation) subsequently implicated ABCB7 in the phenotype
of acquired sideroblastic anemia (RARS).54 In a recent study, we
performed an integrative analysis in MDS and the strongest
association found was between the presence of SF3B1 mutations
and marked downregulation of ABCB7.55 Given the strong
correlation between SF3B1 mutations and the presence of RS,5
our data suggested a three-way association among SF3B1
mutation, ABCB7 downregulation and the occurrence of RS.
Therefore, the marked downregulation of ABCB7 observed in
MDS patients with RARS has been recognized as an important
ﬁnding for several years; however, the mechanism underlying the
downregulation of this gene in MDS has remained a mystery.
In the current study, the use of a pipeline that can detect cryptic
splicing events has enabled the identiﬁcation of A3SS usage of
ABCB7 in the HSC of SF3B1-mutant MDS patients. Importantly, this
event leads to aberrant splicing of the ABCB7 mRNA transcript,
resulting in the addition of seven amino acids, including a
premature termination codon, to the protein sequence in patient
samples. It is recognized that the presence of premature
termination codons can lead to degradation of the mRNA
transcript by NMD,41 and we hypothesized that this event
underlies the marked downregulation of ABCB7 observed in the
HSCs of SF3B1-mutant MDS patients. This mechanism is strongly
supported by our data on cultured SF3B1-mutant MDS erythro-
blasts treated with the NMD inhibitor cycloheximide, showing that
the aberrantly spliced ABCB7 transcript is targeted by NMD in
erythroid cells. Importantly, we next showed that the aberrantly
spliced ABCB7 transcript was present in the myeloid cell line K562
in which the SF3B1 mutation was introduced using CRISPR/Cas9
gene editing, and in the pancreatic cell line Panc 05.04 (which is
mutant for SF3B1). Treatment of these two cell lines with
cycloheximide resulted in an increase of the aberrantly spliced
form of the ABCB7 transcript. These data provide strong evidence
that the SF3B1 mutation leads to aberrant ABCB7 splicing and
downregulation via NMD in human myeloid cells and other cancer
cells. Aberrant splicing of ABCB7 has been reported recently in an
isogenic SF3B1-mutant pre-B ALL cell line in another study.39 We
suggest that downregulation of the iron exporter ABCB7 resulting
from aberrant splicing of the mRNA transcript leading to NMD
underlies the increased mitochondrial iron accumulation found in
MDS patients with RS. Our data provide an important link between
inherited and acquired forms of sideroblastic anemia.
It is possible that the detection of aberrantly spliced target
genes, in particular ABCB7, by RT-PCR could form the basis of a
new diagnostic test for SF3B1-mutated MDS and may provide
valuable information in cases with suspected MDS.
Our study is the ﬁrst to describe the cryptic splicing events that
occur in the hematopoietic progenitor cells of SF3B1-mutant MDS.
These data illuminate the downstream target genes that may have
a role in the development of the MDS phenotype, and further our
understanding of the effect of SF3B1 mutations on splicing in
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malignancy. We demonstrate a mechanism linking the presence of
SF3B1 mutation in MDS RARS patients and the NMD-induced
marked downregulation of the iron transporter ABCB7, and
provide strong evidence supporting a critical role of ABCB7 in
the development of the RS phenotype. ABCB7 might represent a
therapeutic target in MDS with RS.
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